Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 8/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 10/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1546641 | 0.91 | ADORA2B (0.56) | ADORA2BADORA1ADORA2AADORA3KLKB1 | |
| SCHEMBL1723697 | 0.90 | ADORA2B (0.52) | ADORA2BADORA1ADORA2AADORA3KLKB1 | |
| SCHEMBL796431 | 0.88 | ADORA2B (0.58) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL1546781 | 0.88 | KLKB1 (0.52) | ADORA2BADORA1ADORA2AADORA3KLKB1 | |
| SCHEMBL8979367 | 0.85 | ADORA2A (0.51) | ADORA2BADORA1ADORA2AADORA3KLKB1 | |
| SCHEMBL5541331 | 0.84 | ADORA2B (0.45) | ADORA2BADORA1ADORA2AADORA3KLKB1 | |
| SCHEMBL8979421 | 0.82 | KLKB1 (0.43) | ADORA2BADORA1ADORA2AADORA3KLKB1 | |
| SCHEMBL1546784 | 0.82 | ADORA2B (0.41) | ADORA2BADORA1ADORA2AADORA3KLKB1 | |
| SCHEMBL5584758 | 0.80 | ROCK1 (0.39) | ADORA2BADORA2AADORA3KMT2AALDH1A1 | |
| SCHEMBL1546131 | 0.80 | ADORA2B (0.57) | ADORA2BADORA1ADORA2AADORA3KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2012-08-30 | — | — | US | disclosed |
| US-8188099-B2 | Method of decreasing hepatotoxic side effects using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110184002-A1 | METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA2A 2/4885 |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA2A 2/4885 |
| US-20110184002-A1 | METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.